Abstract
Single-agent therapy with paclitaxel is effective against both squamous cell carcinoma and adenocarcinoma of the oesophagus. However, only limited data are available on the combination of paclitaxel with other cytotoxic drugs in this entity. Patients with unresectable stage III, recurrent or metastatic tumours were treated in a multicentre setting with paclitaxel 90 mg m(-2) given over 3 h intravenously, followed by cisplatin 50 mg m(-2). The courses were repeated every 14 days. Twenty patients with squamous cell carcinoma or adenocarcinoma of the oesophagus were evaluable for response. The overall remission rate was 40% (8/20), including 15% (3/20) clinically complete responses. Clinical benefit response, defined as relief of dysphagia and/or significant gain in weight, was achieved in 70% of the patients. Neutropenia of CTC grade 3 occurred only in 10% of the patients; no grade 4 neutropenia and no severe thrombocytopenia was encountered. CTC grade 4 neurotoxicity was seen in 5% of patients. Cisplatin/paclitaxel administered every 14 days, was effective in patients with poor prognosis oesophageal cancer and toxicity was acceptable.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ajani J. A. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol. 1994 Aug;21(4):474–482. [PubMed] [Google Scholar]
- Ajani J. A., Ilson D. H., Daugherty K., Pazdur R., Lynch P. M., Kelsen D. P. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994 Jul 20;86(14):1086–1091. doi: 10.1093/jnci/86.14.1086. [DOI] [PubMed] [Google Scholar]
- Ajani J. A., Ryan B., Rich T. A., McMurtrey M., Roth J. A., DeCaro L., Levin B., Mountain C. Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur J Cancer. 1992;28A(4-5):880–884. doi: 10.1016/0959-8049(92)90140-w. [DOI] [PubMed] [Google Scholar]
- Coia L. R. Chemoradiation as primary management of esophageal cancer. Semin Oncol. 1994 Aug;21(4):483–492. [PubMed] [Google Scholar]
- Gelmon K. A., O'Reilly S. E., Tolcher A. W., Campbell C., Bryce C., Ragaz J., Coppin C., Plenderleith I. H., Ayers D., McDermott B. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol. 1996 Apr;14(4):1185–1191. doi: 10.1200/JCO.1996.14.4.1185. [DOI] [PubMed] [Google Scholar]
- Hilgenberg A. D., Carey R. W., Wilkins E. W., Jr, Choi N. C., Mathisen D. J., Grillo H. C. Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus. Ann Thorac Surg. 1988 Apr;45(4):357–363. doi: 10.1016/s0003-4975(98)90004-2. [DOI] [PubMed] [Google Scholar]
- Kok T. C., Van der Gaast A., Dees J., Eykenboom W. M., Van Overhagen H., Stoter G., Tilanus H. W., Splinter T. A. Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. Br J Cancer. 1996 Sep;74(6):980–984. doi: 10.1038/bjc.1996.469. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Spiridonidis C. H., Laufman L. R., Jones J. J., Gray D. J., Cho C. C., Young D. C. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma. Cancer. 1996 Nov 15;78(10):2070–2077. [PubMed] [Google Scholar]
- Stahl M., Wilke H., Meyer H. J., Preusser P., Berns T., Fink U., Achterrath W., Knipp H., Harstrick A., Berger M. 5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus. Eur J Cancer. 1994;30A(3):325–328. doi: 10.1016/0959-8049(94)90250-x. [DOI] [PubMed] [Google Scholar]